advertisement
Li S 21
Showing records 1 to 21 | Display all abstracts from Li S98544 Brain Functional Network Analysis of Patients with Primary Angle-Closure Glaucoma
Liu D
Disease markers 2022; 2022: 2731007
99128 The Efficacy of Simultaneous Injection of Dexamethasone Implant and Ranibizumab Into Vitreous Cavity on Macular Edema Secondary to Central Retinal Vein Occlusion
Du X
Frontiers in pharmacology 2022; 13: 842805
98580 Targeting Pyroptotic Cell Death Pathways in Retinal Disease
Zhao M
Frontiers in medicine 2021; 8: 802063
98497 Serum complement component 3, complement component 4 and complement component 1q levels predict progressive visual field loss in older women with primary angle closure glaucoma
Li S
British Journal of Ophthalmology 2023; 107: 828-835
99128 The Efficacy of Simultaneous Injection of Dexamethasone Implant and Ranibizumab Into Vitreous Cavity on Macular Edema Secondary to Central Retinal Vein Occlusion
Sheng Y
Frontiers in pharmacology 2022; 13: 842805
98580 Targeting Pyroptotic Cell Death Pathways in Retinal Disease
Li S
Frontiers in medicine 2021; 8: 802063
98497 Serum complement component 3, complement component 4 and complement component 1q levels predict progressive visual field loss in older women with primary angle closure glaucoma
Qiu Y
British Journal of Ophthalmology 2023; 107: 828-835
98544 Brain Functional Network Analysis of Patients with Primary Angle-Closure Glaucoma
Gao J; You T
Disease markers 2022; 2022: 2731007
98580 Targeting Pyroptotic Cell Death Pathways in Retinal Disease
Matsubara JA
Frontiers in medicine 2021; 8: 802063
98497 Serum complement component 3, complement component 4 and complement component 1q levels predict progressive visual field loss in older women with primary angle closure glaucoma
Yu J
British Journal of Ophthalmology 2023; 107: 828-835
99128 The Efficacy of Simultaneous Injection of Dexamethasone Implant and Ranibizumab Into Vitreous Cavity on Macular Edema Secondary to Central Retinal Vein Occlusion
Shi Y; Du M
Frontiers in pharmacology 2022; 13: 842805
98497 Serum complement component 3, complement component 4 and complement component 1q levels predict progressive visual field loss in older women with primary angle closure glaucoma
Shao M
British Journal of Ophthalmology 2023; 107: 828-835
98544 Brain Functional Network Analysis of Patients with Primary Angle-Closure Glaucoma
Li S
Disease markers 2022; 2022: 2731007
98497 Serum complement component 3, complement component 4 and complement component 1q levels predict progressive visual field loss in older women with primary angle closure glaucoma
Li Y
British Journal of Ophthalmology 2023; 107: 828-835
98544 Brain Functional Network Analysis of Patients with Primary Angle-Closure Glaucoma
Cai F
Disease markers 2022; 2022: 2731007
99128 The Efficacy of Simultaneous Injection of Dexamethasone Implant and Ranibizumab Into Vitreous Cavity on Macular Edema Secondary to Central Retinal Vein Occlusion
Guo Y
Frontiers in pharmacology 2022; 13: 842805
98544 Brain Functional Network Analysis of Patients with Primary Angle-Closure Glaucoma
Pei C
Disease markers 2022; 2022: 2731007
98497 Serum complement component 3, complement component 4 and complement component 1q levels predict progressive visual field loss in older women with primary angle closure glaucoma
Cao W
British Journal of Ophthalmology 2023; 107: 828-835
99128 The Efficacy of Simultaneous Injection of Dexamethasone Implant and Ranibizumab Into Vitreous Cavity on Macular Edema Secondary to Central Retinal Vein Occlusion
Li S
Frontiers in pharmacology 2022; 13: 842805
98497 Serum complement component 3, complement component 4 and complement component 1q levels predict progressive visual field loss in older women with primary angle closure glaucoma
Sun X
British Journal of Ophthalmology 2023; 107: 828-835
98544 Brain Functional Network Analysis of Patients with Primary Angle-Closure Glaucoma
Zeng X
Disease markers 2022; 2022: 2731007